Standard BioTools Inc. (LAB) Bundle
A Brief History of Standard BioTools Inc. (LAB)
Company Overview
Standard BioTools Inc. (NASDAQ: LAB) is a life sciences technology company headquartered in South San Francisco, California.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Annual Revenue | $395.4 million |
| Net Loss | $92.1 million |
| Cash and Investments | $308.6 million |
Key Product Lines
- Genomics Research Instruments
- Single-Cell Multiomics Solutions
- Spatial Biology Technologies
Market Position
Standard BioTools focuses on developing high-performance technologies for life sciences research and precision medicine applications.
Recent Corporate Developments
- Completed strategic restructuring in 2023
- Reduced workforce by approximately 20%
- Implemented cost-cutting measures to improve operational efficiency
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| Stock Price (as of February 2024) | $1.23 per share |
| Market Capitalization | $175.6 million |
Research and Development
R&D expenses for 2023 totaled $146.2 million, representing 37% of annual revenue.
A Who Owns Standard BioTools Inc. (LAB)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 4,945,227 | 16.25% |
| BlackRock Inc | 3,872,415 | 12.73% |
| Dimensional Fund Advisors LP | 2,103,689 | 6.92% |
Top Individual Shareholders
- Stephen Tang - President and CEO
- Marc Jones - Chief Financial Officer
- Michael Egholm - Chief Technology Officer
Ownership Structure
Public Float: 30,414,000 shares
Insider Ownership: 5.2%
Institutional Ownership: 72.6%
Standard BioTools Inc. (LAB) Mission Statement
Company Overview
Standard BioTools Inc. trades on NASDAQ under ticker symbol LAB. As of February 2024, the company's market capitalization is $269.42 million. Fiscal year 2023 revenue was $116.1 million.
Mission Statement Components
The mission statement focuses on advancing life science research through innovative technology platforms.
| Key Strategic Areas | Focus Details |
|---|---|
| Research Technology | Single-cell and spatial biology solutions |
| Product Categories | Genomics, proteomics, and cellular analysis instruments |
| Annual R&D Investment | $35.4 million in 2023 |
Strategic Objectives
- Develop cutting-edge life science research technologies
- Provide high-precision analytical instruments
- Support scientific discovery across academic and pharmaceutical sectors
Financial Performance Metrics
| Financial Indicator | 2023 Value |
|---|---|
| Gross Margin | 48.3% |
| Operating Expenses | $82.7 million |
| Net Income | $-14.2 million |
Research and Development Focus
Key technological platforms include:
- Helios mass cytometry systems
- Hyper-precise single-cell sequencing technologies
- Spatial genomics analysis tools
Global Presence
Operational presence in United States, Europe, and Asia-Pacific regions. Total employee count: 385 as of Q4 2023.
How Standard BioTools Inc. (LAB) Works
Company Overview
Standard BioTools Inc. is a life sciences technology company headquartered in South San Francisco, California. The company specializes in developing and manufacturing multiplex protein detection and single-cell technologies.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $134.7 million |
| Net Loss | $52.3 million |
| Cash and Cash Equivalents | $87.6 million |
Product Portfolio
- Imaging Systems
- Multiplexing Immunoassay Platforms
- Single-Cell Proteomics Solutions
- Genomic Research Tools
Market Segments
Standard BioTools serves multiple research markets including:
- Academic Research Institutions
- Pharmaceutical Companies
- Biotechnology Firms
- Clinical Diagnostic Laboratories
Technology Platforms
| Platform | Key Characteristics |
|---|---|
| Maxpar | Mass Cytometry Technology |
| Helios | Single-Cell Mass Cytometry System |
Research and Development
R&D Expenses in 2023: $45.2 million
Operational Details
- Employees: Approximately 350
- Publicly Traded: NASDAQ: LAB
- Founded: 1996
How Standard BioTools Inc. (LAB) Makes Money
Revenue Streams
Standard BioTools Inc. reported total revenue of $96.6 million for the fiscal year 2023.
| Revenue Category | Amount (in millions) | Percentage |
|---|---|---|
| Genomics Systems | $42.3 | 43.8% |
| Proteomics Systems | $31.5 | 32.6% |
| Consumables | $22.8 | 23.6% |
Product Segments
- Genomics Solutions
- Proteomics Solutions
- Consumables and Reagents
Market Channels
Standard BioTools generates revenue through:
- Direct sales to research institutions
- Sales through scientific equipment distributors
- Online platform sales
Financial Performance
Gross margin for 2023: 52.4%
Operating expenses: $74.2 million
| Financial Metric | 2023 Value |
|---|---|
| Net Income | -$18.7 million |
| Cash and Equivalents | $127.3 million |
Geographic Revenue Distribution
| Region | Revenue Percentage |
|---|---|
| North America | 58.3% |
| Europe | 27.6% |
| Asia-Pacific | 14.1% |
Standard BioTools Inc. (LAB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.